AcelRx Pharmaceuticals (ACRX) Receives Daily Media Sentiment Score of 0.22

News coverage about AcelRx Pharmaceuticals (NASDAQ:ACRX) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.443295350099 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Several research analysts recently commented on the stock. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Piper Jaffray Companies set a $3.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Finally, ValuEngine raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Shares of AcelRx Pharmaceuticals (ACRX) opened at 2.95 on Monday. The firm’s market cap is $133.87 million. The stock’s 50 day moving average is $2.77 and its 200-day moving average is $2.78. AcelRx Pharmaceuticals has a 52-week low of $1.95 and a 52-week high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The company had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. Equities analysts anticipate that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current fiscal year.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $2.40, for a total transaction of $2,100,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 28.10% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “AcelRx Pharmaceuticals (ACRX) Receives Daily Media Sentiment Score of 0.22” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

What are top analysts saying about AcelRx Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AcelRx Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit